Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BeyondSpring Inc. (BYSI)
USD1.27
-0.06 (-4.51%)
US NASDAQ Healthcare Biotechnology
Address
28 Liberty Street 10005
Florham Park, NY, US
Florham Park, NY, US
CEO
Lan Huang
Website
beyondspringpharma.com
IPO
2017-03-09
CIK 1677940 ISIN KYG108301006
Description
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.27
-0.06 (-4.51%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
18.2K
Beta
0.43
Float Shares
31.20M
Free Float %
75.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +4.32% | +1.40% | -17.14% | +14.17% | -29.61% | -11.04% | -15.70% | +43.56% | -84.77% | -91.37% | -91.37% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
1.27
DCF (Unlevered)
0.18
-86.1%
DCF (Levered)
0.18
-85.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | -1 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-31.95
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+28.6% Q1'26: -145.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.7% ★ Q1'26: +2.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
1.35M
est: 1.27M (+6.7%)
|
1.35M
est: 31.01M (-95.6%)
|
—
est: 1.35M (-100.0%)
|
—
est: 83.68M (-100.0%)
|
—
est: 137.95M (-100.0%)
|
194.65M
194.65M – 194.65M
+41.1% YoY
|
| EBITDA |
-64.49M
est: -253.3K (-25,356.6%)
|
-34.96M
est: -6.20M (-463.6%)
|
-13.62M
est: -270.2K (-4,941.1%)
|
-8.47M
est: 16.74M (-150.6%)
|
-8.86M
est: 27.59M (-132.1%)
|
38.93M
38.93M – 38.93M
+41.1% YoY
|
| EBIT |
-64.55M
est: -253.3K (-25,380.7%)
|
-36.10M
est: -6.20M (-482.0%)
|
-13.92M
est: -270.2K (-5,052.9%)
|
-8.75M
est: 16.74M (-152.3%)
|
-8.95M
est: 27.59M (-132.4%)
|
38.93M
38.93M – 38.93M
+41.1% YoY
|
| Net Income |
-64.18M
est: -61.59M (-4.2%)
|
-33.28M
est: -34.97M (+4.8%)
|
-21.03M
est: -18.67M (-12.6%)
|
-11.12M
est: 10.10M (-210.1%)
|
-7.99M
est: 44.45M (-118.0%)
|
80.00M
80.00M – 80.00M
+80.0% YoY
|
| SGA |
30.70M
est: 40.51M (-24.2%)
|
13.01M
est: 991.82M (-98.7%)
|
7.51M
est: 43.20M (-82.6%)
|
6.11M
est: 591.72M (-99.0%)
|
4.56M
est: 975.43M (-99.5%)
|
1.38B
1.38B – 1.38B
+41.1% YoY
|
| EPS |
-1.64
est: -1.55 (-5.8%)
|
-0.85
est: -0.88 (+3.4%)
|
-0.54
est: -0.47 (-14.9%)
|
-0.28
est: 0.25 (-212.0%)
|
-0.20
est: 1.10 (-118.2%)
|
1.98
1.98 – 1.98
+80.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-20.32M
OE per share TTM
-0.50
Owner's Yield
-33.08%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
683.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
4
Total invested
29.1K
Insider transactions (90d)
0
Beneficial owners (>5%)
18
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Lan Huang | 11.37M | 49.03% | — | 11.37M | — | 11.37M | IN | British Virgin Islands | 2019-02-20 | ↗ |
| 2 | Linqing Jia | 11.37M | 49.03% | — | 11.37M | — | 11.37M | IN | British Virgin Islands | 2019-02-20 | ↗ |
| 3 | Decheng Capital Management III (Cayman), LLC | 4.96M | 12.67% | 4.96M | 4.96M | 4.96M | 4.96M | IA | — | 2022-02-14 | ↗ |
| 4 | Fairy Eagle Investment Limited | 4.62M | 19.93% | — | 4.62M | — | 4.62M | OO | British Virgin Islands | 2019-02-20 | ↗ |
| 5 | Ever Regal Group Limited | 3.66M | 15.79% | — | 3.66M | — | 3.66M | OO | British Virgin Islands | 2019-02-20 | ↗ |
| 6 | Cui | 3.46M | 11.30% | — | 3.46M | — | 10.00 | IN | States | 2020-07-27 | ↗ |
| 7 | Rosy Time Holdings Limited | 2.19M | 9.45% | — | 2.19M | — | 2.19M | OO | British Virgin Islands | 2019-02-20 | ↗ |
| 8 | (10) | 2.11M | 9.73% | 2.11M | — | 2.11M | — | IN | United States America | 2018-01-10 | ↗ |
| 9 | Capital China Life Sciences USD Fund III, L.P. | 1.73M | 5.70% | — | 1.73M | — | 10.00 | PN | Islands | 2020-07-27 | ↗ |
| 10 | Capital Management III (Cayman), LLC | 1.73M | 5.70% | — | 1.73M | — | 10.00 | OO | Islands | 2020-07-27 | ↗ |
| 11 | Capital China Life Sciences USD Fund II, L.P. | 1.73M | 5.70% | — | 1.73M | — | 10.00 | PN | Islands | 2020-07-27 | ↗ |
| 12 | Capital Management II (Cayman), LLC | 1.73M | 5.70% | — | 1.73M | — | 10.00 | OO | Islands | 2020-07-27 | ↗ |
| 13 | Xiangmin Cui | 1.55M | 6.00% | — | 1.55M | — | — | IN | Cayman Islands | 2019-08-02 | ↗ |
| 14 | Shenzhen Sangel Capital Management Limited Company | 1.25M | 3.22% | 1.07M | 187.8K | 1.07M | 187.8K | OO | — | 2022-02-14 | ↗ |
| 15 | Fund II, L.P. | 775.9K | 3.00% | — | 775.9K | — | — | PN | Cayman Islands | 2019-08-02 | ↗ |
| 16 | Fund III, L.P. | 775.9K | 3.00% | — | 775.9K | — | — | PN | Cayman Islands | 2019-08-02 | ↗ |
| 17 | LLC | 775.9K | 3.00% | — | 775.9K | — | — | OO | Cayman Islands | 2019-08-02 | ↗ |
| 18 | 13-4064930 | 31.2K | 0.10% | 31.2K | — | 31.2K | — | IA | Delaware | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
4
-22 vs prev Q
New positions
1
Closed positions
21
Increased
1
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | DECHENG CAPITAL LLC | 3.80M -485.4K (-11.3%) | 6.20M -1.6M (-20.1%) | 9.43% -1.204 pp | 0.83% -0.520 pp | USD0.90 +81.1% | 9 qtrs — |
| 2 | VANGUARD GROUP INC | 759.0K +212.3K (+38.8%) | 1.24M +247.6K (+25.0%) | 1.88% +0.526 pp | 0.00% +0.000 pp | USD2.13 -23.5% | 3 qtrs — |
| 3 | BLACKROCK, INC. | 670.5K +30.8K (+4.8%) | 1.09M -64.9K (-5.6%) | 1.66% +0.076 pp | 0.00% +0.000 pp | USD2.29 -28.8% | 6 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 368.7K +53.2K (+16.9%) | 601.3K +29.9K (+5.2%) | 0.91% +0.132 pp | 0.00% +0.000 pp | USD2.93 -44.4% | 35 qtrs — |
| 5 | STATE STREET CORP | 231.1K +231.1K (+100.0%) | 376.7K +376.7K (+100.0%) | 0.57% +0.573 pp | 0.00% +0.000 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 6 | WELLS FARGO & COMPANY/MN | 175.0K +— (+0.0%) | 285.3K -31.5K (-9.9%) | 0.43% +0.000 pp | 0.00% +0.000 pp | USD2.35 -30.6% | 3 qtrs — |
| 7 | NORTHERN TRUST CORP | 69.3K -1.5K (-2.1%) | 112.9K -15.2K (-11.9%) | 0.17% -0.004 pp | 0.00% +0.000 pp | USD3.64 -55.2% | 27 qtrs — |
| 8 | JANE STREET GROUP, LLC | 39.3K +300.0 (+0.8%) | 64.1K -6.5K (-9.3%) | 0.10% +0.001 pp | 0.00% +0.000 pp | USD2.34 -30.3% | 3 qtrs — |
| 9 | CITADEL ADVISORS LLC | 32.1K +7.6K (+31.0%) | 52.3K +8.0K (+18.0%) | 0.08% +0.019 pp | 0.00% +0.000 pp | USD2.18 -25.2% | 21 qtrs — |
| 10 | TANAKA CAPITAL MANAGEMENT INC | 26.3K +— (+0.0%) | 43.0K -5.0K (-10.4%) | 0.07% +0.000 pp | 0.08% -0.008 pp | USD1.81 -9.9% | 2 qtrs — |
| 11 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 25.0K -6.5K (-20.6%) | 40.8K -16.3K (-28.5%) | 0.06% -0.016 pp | 0.00% +0.000 pp | USD2.35 -30.6% | 18 qtrs — |
| 12 | RENAISSANCE TECHNOLOGIES LLC | 11.0K -600.0 (-5.2%) | 17.9K -3.1K (-14.6%) | 0.03% -0.002 pp | 0.00% +0.000 pp | USD2.47 -34.0% | 7 qtrs — |
| 13 | BANK OF AMERICA CORP /DE/ | 7.5K -12.0 (-0.2%) | 12.3K -1.4K (-10.1%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD5.01 -67.5% | 29 qtrs — |
| 14 | MORGAN STANLEY | 5.0K -2.9K (-36.8%) | 8.2K -6.2K (-43.1%) | 0.01% -0.007 pp | 0.00% +0.000 pp | USD9.71 -83.2% | 33 qtrs — |
| 15 | NATIONAL BANK OF CANADA /FI/ | 2.9K +— (+0.0%) | 4.7K -517.0 (-10.0%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD2.20 -25.9% | 16 qtrs — |
| 16 | UBS GROUP AG | 2.2K +901.0 (+67.3%) | 3.7K +1.2K (+50.7%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD1.71 -4.7% | 30 qtrs — |
| 17 | TRIFECTA CAPITAL ADVISORS, LLC | 1.5K +— (+0.0%) | 2.4K -270.0 (-9.9%) | 0.00% +0.000 pp | 0.00% 0.000 pp | USD1.44 +13.2% | 4 qtrs — |
| 18 | TOWER RESEARCH CAPITAL LLC (TRC) | 330.00 -1.1K (-77.1%) | 538.00 -2.1K (-79.4%) | 0.00% -0.003 pp | 0.00% 0.000 pp | USD1.90 -14.2% | 3 qtrs — |
| 19 | JPMORGAN CHASE & CO | 294.00 +54.0 (+22.5%) | 479.00 +45.0 (+10.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.68 -3.0% | 5 qtrs — |
| 20 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 151.00 +— (+0.0%) | 246.00 -27.0 (-9.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.81 -9.9% | 2 qtrs — |
| 21 | ADVISOR GROUP HOLDINGS, INC. | 100.00 +100.0 (+100.0%) | 163.00 +163.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.63 +0.0% | 1 qtrs NEW |
| 22 | SBI SECURITIES CO., LTD. | 87.00 +— (+0.0%) | 142.00 -15.0 (-9.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.62 +0.6% | 5 qtrs — |
| 23 | BNP PARIBAS ARBITRAGE, SNC | 9.00 +— (+0.0%) | 15.00 -1.0 (-6.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.33 -30.0% | 3 qtrs — |
| 24 | CITIGROUP INC | 1.00 +1.0 (+100.0%) | 2.00 +2.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +63.0% | 1 qtrs NEW |
| 25 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | — -1.1K (-100.0%) | — -2.0K (-100.0%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 26 | BARCLAYS PLC | — -4.0 (-100.0%) | — -9.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 9 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Micro-Cap ETF IWC | 0.01% | 151.9K | 0.60% |
| 2 | Vanguard Extended Market ETF VXF | 0.00% | 563.4K | 0.05% |
| 3 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 946.40 | 0.03% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 2.6K | 0.17% |
| 5 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 191.94 | 0.17% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 444.1K | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 973.42 | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 529.80 | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 213.97 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 23.62 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
6
Sells
0
Shares acquired
112.4K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+112,365
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Xu Sihai | Director | A-Award | A | Stock Options (right to buy) | 18,689 | 1.64 | 30.6K | 18,689 | D | ↗ |
| 2026-04-01 | Majeti Jiangwen | Director | A-Award | A | Stock Options (right to buy) | 21,730 | 1.64 | 35.6K | 21,730 | D | ↗ |
| 2026-04-01 | Lu Yingjuan June | Officer | A-Award | A | Stock Options (right to buy) | 17,840 | 1.64 | 29.3K | 17,840 | D | ↗ |
| 2026-04-01 | Kirkby Matthew | Director | A-Award | A | Stock Options (right to buy) | 23,902 | 1.64 | 39.2K | 23,902 | D | ↗ |
| 2026-04-01 | Huang Lan | Director / Officer / 10% Owner | A-Award | A | Stock Options (right to buy) | 11,514 | 1.80 | 20.8K | 11,514 | D | ↗ |
| 2026-04-01 | Fabbio Patrick | Director | A-Award | A | Stock Options (right to buy) | 22,165 | 1.64 | 36.4K | 22,165 | D | ↗ |
| 2026-04-01 | Delaney Brendan | Director | A-Award | A | Stock Options (right to buy) | 20,427 | 1.64 | 33.5K | 20,427 | D | ↗ |
| 2025-10-17 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 45,513 | 1.76 | 80.1K | 1,518,893 | I | ↗ |
| 2025-10-16 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 85,798 | 1.72 | 147.6K | 1,564,406 | I | ↗ |
| 2025-10-15 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 17,960 | 1.65 | 29.6K | 1,650,204 | I | ↗ |
| 2025-10-14 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 28,495 | 1.65 | 47.0K | 1,668,164 | I | ↗ |
| 2025-10-13 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 107,361 | 1.70 | 182.5K | 1,696,659 | I | ↗ |
| 2025-10-10 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,390 | 1.77 | 4.2K | 1,804,020 | I | ↗ |
| 2025-10-09 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 3,979 | 1.81 | 7.2K | 1,806,410 | I | ↗ |
| 2025-10-08 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 7,507 | 1.77 | 13.3K | 1,810,389 | I | ↗ |
| 2025-10-07 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,100 | 1.79 | 3.8K | 1,817,896 | I | ↗ |
| 2025-10-06 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 17,500 | 1.78 | 31.2K | 1,819,996 | I | ↗ |
| 2025-10-03 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 600 | 1.76 | 1.1K | 1,837,496 | I | ↗ |
| 2025-10-02 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 600 | 1.73 | 1.0K | 1,838,096 | I | ↗ |
| 2025-10-01 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,601 | 1.80 | 4.7K | 1,838,696 | I | ↗ |
| 2025-09-30 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 4,464 | 1.81 | 8.1K | 1,841,297 | I | ↗ |
| 2025-09-29 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 500 | 1.75 | 875.00 | 1,845,761 | I | ↗ |
| 2025-09-26 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 600 | 1.68 | 1.0K | 1,846,261 | I | ↗ |
| 2025-09-25 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 700 | 1.66 | 1.2K | 1,846,861 | I | ↗ |
| 2025-09-24 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,256 | 1.68 | 3.8K | 1,847,561 | I | ↗ |
| 2025-09-23 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 4,106 | 1.72 | 7.1K | 1,849,817 | I | ↗ |
| 2025-09-22 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 5,410 | 1.83 | 9.9K | 1,853,923 | I | ↗ |
| 2025-09-19 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 3,656 | 1.79 | 6.5K | 1,859,333 | I | ↗ |
| 2025-09-18 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 5,307 | 1.74 | 9.2K | 1,862,989 | I | ↗ |
| 2025-09-17 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,304 | 1.83 | 4.2K | 1,868,296 | I | ↗ |
| 2025-09-16 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 840 | 1.88 | 1.6K | 1,870,600 | I | ↗ |
| 2025-09-15 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,570 | 1.84 | 4.7K | 1,871,440 | I | ↗ |
| 2025-09-12 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 700 | 1.85 | 1.3K | 1,874,010 | I | ↗ |
| 2025-09-11 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 3,820 | 1.90 | 7.3K | 1,874,710 | I | ↗ |
| 2025-09-10 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 8,176 | 1.93 | 15.8K | 1,878,530 | I | ↗ |
| 2025-09-09 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 9,050 | 1.97 | 17.8K | 1,886,706 | I | ↗ |
| 2025-09-08 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 7,090 | 1.93 | 13.7K | 1,895,756 | I | ↗ |
| 2025-09-05 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 1,106 | 1.86 | 2.1K | 1,902,846 | I | ↗ |
| 2025-09-04 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 803 | 1.82 | 1.5K | 1,903,952 | I | ↗ |
| 2025-09-03 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 1,270 | 1.81 | 2.3K | 1,904,755 | I | ↗ |
| 2025-09-02 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,800 | 1.78 | 5.0K | 1,906,025 | I | ↗ |
| 2025-08-29 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 800 | 1.74 | 1.4K | 1,908,825 | I | ↗ |
| 2025-08-28 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 809 | 1.81 | 1.5K | 1,909,625 | I | ↗ |
| 2025-08-27 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 1,300 | 1.78 | 2.3K | 1,910,434 | I | ↗ |
| 2025-08-26 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,000 | 1.79 | 3.6K | 1,911,734 | I | ↗ |
| 2025-08-25 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 300 | 1.77 | 531.00 | 1,913,734 | I | ↗ |
| 2025-08-22 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,376 | 1.75 | 4.2K | 1,914,034 | I | ↗ |
| 2025-08-21 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 3,034 | 1.79 | 5.4K | 1,916,410 | I | ↗ |
| 2025-08-20 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 3,456 | 1.74 | 6.0K | 1,919,444 | I | ↗ |
| 2025-08-19 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 3,604 | 1.77 | 6.4K | 1,922,900 | I | ↗ |
| 2025-08-18 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 47,668 | 2.03 | 96.8K | 1,926,504 | I | ↗ |
| 2025-08-15 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,900 | 2.00 | 5.8K | 1,974,172 | I | ↗ |
| 2025-08-14 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,000 | 2.00 | 4.0K | 1,977,072 | I | ↗ |
| 2025-08-04 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,196 | 2.18 | 4.8K | 891,734 | I | ↗ |
| 2025-07-18 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 900 | 2.20 | 2.0K | 893,930 | I | ↗ |
| 2025-07-17 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 20,572 | 2.19 | 45.1K | 894,830 | I | ↗ |
| 2025-07-16 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 5,396 | 2.24 | 12.1K | 915,402 | I | ↗ |
| 2025-07-15 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 2,152 | 2.28 | 4.9K | 920,798 | I | ↗ |
| 2025-07-14 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 801 | 2.29 | 1.8K | 922,950 | I | ↗ |
| 2025-07-11 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 246 | 2.29 | 563.34 | 923,751 | I | ↗ |
| 2025-07-10 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 768 | 2.28 | 1.8K | 923,997 | I | ↗ |
| 2025-07-09 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 252 | 2.27 | 572.04 | 924,765 | I | ↗ |
| 2025-07-08 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 9,059 | 2.29 | 20.7K | 925,017 | I | ↗ |
| 2025-07-02 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 324 | 2.42 | 784.08 | 934,076 | I | ↗ |
| 2025-07-01 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 600 | 2.43 | 1.5K | 934,400 | I | ↗ |
| 2025-06-23 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 1,700 | 3.09 | 5.3K | 1,617,409 | I | ↗ |
| 2025-06-20 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 225,217 | 3.16 | 711.7K | 1,619,109 | I | ↗ |
| 2025-06-18 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 59,253 | 3.17 | 187.8K | 1,844,326 | I | ↗ |
| 2025-06-17 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | S-Sale | D | Ordinary Shares | 5,000 | 3.23 | 16.2K | 995,000 | I | ↗ |
| 2025-04-21 | Xu Sihai | Director | A-Award | A | Stock Options (right to buy) | 19,852 | 1.31 | 26.0K | 19,852 | D | ↗ |
| 2025-04-21 | Majeti Jiangwen | Director | A-Award | A | Stock Options (right to buy) | 23,300 | 1.31 | 30.5K | 23,300 | D | ↗ |
| 2025-04-21 | Lu Yingjuan June | Officer | A-Award | A | Stock Options (right to buy) | 18,981 | 1.31 | 24.9K | 18,981 | D | ↗ |
| 2025-04-21 | Kirkby Matthew | Director | A-Award | A | Stock Options (right to buy) | 25,763 | 1.31 | 33.7K | 25,763 | D | ↗ |
| 2025-04-21 | Huang Lan | Director / Officer / 10% Owner | A-Award | A | Stock Options (right to buy) | 43,630 | 1.44 | 62.9K | 43,630 | D | ↗ |
| 2025-04-21 | Fabbio Patrick | Director | A-Award | A | Stock Options (right to buy) | 23,793 | 1.31 | 31.2K | 23,793 | D | ↗ |
| 2025-04-21 | Delaney Brendan | Director | A-Award | A | Stock Options (right to buy) | 21,822 | 1.31 | 28.6K | 21,822 | D | ↗ |
| 2025-01-02 | Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | — | — | Ordinary Shares | 0 | 0.00 | — | 1,903,579 | I | ↗ |
| 2024-12-31 | Xu Sihai | Director | — | — | Stock Options (right to buy) | 10,000 | 0.98 | 9.8K | 0 | D | ↗ |
| 2024-12-31 | Majeti Jiangwen | Director | — | — | Ordinary Shares | 0 | 0.00 | — | 50,914 | D | ↗ |
| 2024-12-31 | Lu Yingjuan June | Officer | — | — | Stock Options (right to buy) | 2,003 | 4.26 | 8.5K | 0 | D | ↗ |
| 2024-12-31 | Kirkby Matthew | Director | — | — | Stock Options (right to buy) | 10,000 | 4.53 | 45.3K | 0 | D | ↗ |
| 2024-12-31 | Huang Lan | Director / Officer | — | — | Stock Options (right to buy) | 90,343 | 4.69 | 423.7K | 0 | D | ↗ |
| 2024-12-31 | Fabbio Patrick | Director | — | — | Stock Options (right to buy) | 15,000 | 2.68 | 40.2K | 0 | D | ↗ |
| 2024-12-31 | Delaney Brendan | Director | — | — | Stock Options (right to buy) | 10,000 | 0.90 | 9.0K | 0 | D | ↗ |
Executive team
Top executives
Shares Outstanding
41.12M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Lan Huang | Co-Founder, Chairman & Chief Executive Officer | 664.7K | — |
| June Lu | Chief Scientific Officer | 329.6K | — |
| John Mao | Senior Vice President of Development | — | — |
| Joy Jia | VP of Finance | — | female |
| Stephen Kilmer | Head of Investor Relations | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BYSI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
